Springfield City Group has finalised an agreement to welcome Aegros into BioPark Australia, enabling the biopharmaceuticals company to develop a new $352 million manufacturing facility.
The proposed new facility is set to be the first developed as part of BioPark Australia, in which multiple biologic industries will co-locate and provide health innovations that will benefit the lives of Australians and beyond.
Aiming to begin operations in 2026, the Aegros facility will ensure Australian patients have access to safe, reliable and affordable plasma medicines that can help fight infection or diseases such as Lupus, promote blood clotting, prevent shock and assist with post-surgical recovery.
The Queensland Government’s Invested in Queensland program is supporting the development in which Aegros plans to set up its new global headquarters in BioPark Australia alongside an advanced production facility.
Springfield City Group Chairman Maha Sinnathamby AM welcomed today’s agreement which enables Aegros to develop a 4.18 hectare site.
“Greater Springfield has been created to enhance human capital and that comes together in this step towards the Aegros facility,” Mr Sinnathamby said.
“This new facility is set to be the first project delivered as part of the new BioPark Australia precinct. Dedicated to attracting industries across commercial, education, health, innovation technology and lifestyle sectors, we envision that other biomedical and innovative companies will soon join Aegros here in Greater Springfield.
“We are very excited about this project and a number of other high-profile projects currently in development in Greater Springfield.”
Construction of the facility will support an estimated 230 jobs. Once operational, the facility is expected to provide 348 long-term jobs in its first four years.
The new Aegros facility aims to process yields of around 90 per cent – ensuring the most medicine per litre of plasma. Positioning the facility in BioPark Australia will allow for production on a large scale. The site will be able to process 1 million litres of plasma per annum, but through its high yield advantage, produce the equivalent of 2 million litres – making the Greater Springfield location one of the largest producers of plasma in the world.
Aegros Founding Executive Chair Professor Hari Nair said the company was looking forward to establishing its facility and taking the commercialisation of its technology to the next level. Professor Nair was part of a signing ceremony this morning with Mr Sinnathamby and Springfield City Group Deputy Chairman Bob Sharpless.
Professor Nair was also in Greater Springfield to speak with Life Sciences Queensland’s panel on Biomanufacturing: Charting the Course for a Sustainable Future, joining experts from across the country. Springfield City Group supported the conversation which featured Dustin Welch, the Group’s General Manager Health.
“The development of HaemaFrac®, our unique fractionation process, has been a 30-year journey for myself and Co-Founder and Managing Director John Manusu,” Professor Nair said. “We are excited HaemaFrac® is going to be used to increase Australia’s ability to meet its own demand for plasma products, reduce the reliance on overseas supply chains, reduce costs for Australian patients, and to develop and deliver fast responses whenever another pandemic arises.
“The global and Australian market for safe, secure and affordable therapeutic plasma and blood products is only increasing. Coupled with Aegros’ significant R&D capability, in collaboration with Queensland’s medical community and universities we are looking to develop new plasma therapies to address diseases with unmet therapeutic needs.
“In this way Aegros is also proud to be able to contribute to the country’s future pandemic preparedness.”